Evaluation of Biomarkers of Traumatic Brain Injury

NCT ID: NCT01426919

Last Updated: 2020-12-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

2011 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-12-31

Study Completion Date

2017-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to evaluate the utility of the Banyan UCH-L1/GFAP Detection Assay as an aid in the evaluation of suspected traumatic brain injury (Glasgow Coma Scale score 9-15) in conjunction with other clinical information within 12 hours of injury to assist in determining the need for a CT scan of the head.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Traumatic Brain Injury

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Traumatic Brain Injury Head Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Suspected traumatic brain injury with head CT

Head CT scan and blood draw within 12 hours of injury

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Head CT scan and blood draw within 12 hours of injury

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* subject is at least 18 years of age at screening
* suspected traumatically induced head injury as a result of insult to the head from external force
* GCS 9-15 at time of informed consent
* workup includes head CT scan as part of clinical emergency care within 3 hours of presenting and within 12 hours of injury
* blood sample collected within 3 hours of presenting and within 12 hours of injury
* subject or legal representative is willing to undergo informed consent

Exclusion Criteria

* participating in an interventional, therapeutic clinical study that may affect the results of this study (an observational study acceptable)
* time of injury cannot be determined
* primary diagnosis of ischemic or hemorrhagic stroke
* venipuncture not feasible
* a condition precluding entry into the CT scanner
* subject has a neurodegenerative disease or other neurological disorder including dementia, Parkinson's disease, multiple sclerosis, seizure disorder, brain tumors, and history of neurosurgery, stroke or TIA within the last 30 days
* administration of blood transfusion after head injury and prior to study blood draw
* subject is otherwise determined by the Investigator to be unsuitable for participation
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

United States Department of Defense

FED

Sponsor Role collaborator

Banyan Biomarkers, Inc

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of California San Diego

San Diego, California, United States

Site Status

Hartford Hospital

Hartford, Connecticut, United States

Site Status

University of Florida

Gainesville, Florida, United States

Site Status

Tallahassee Neurological Clinic

Tallahassee, Florida, United States

Site Status

University of Massachusetts Medical School

Worcester, Massachusetts, United States

Site Status

Wayne State University - Detroit Receiving Hospital

Detroit, Michigan, United States

Site Status

Wayne State University - Sinai Grace Hospital

Detroit, Michigan, United States

Site Status

Washington University

St Louis, Missouri, United States

Site Status

University of Rochester Medical Center

Rochester, New York, United States

Site Status

University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, United States

Site Status

University of Pittsburgh

Pittsburgh, Pennsylvania, United States

Site Status

University Medical Center Brackenridge

Austin, Texas, United States

Site Status

Baylor College of Medicine/Ben Taub General Hospital

Houston, Texas, United States

Site Status

University of Virginia

Charlottesville, Virginia, United States

Site Status

Carilion New River Valley

Christiansburg, Virginia, United States

Site Status

Virginia Commonwealth University

Richmond, Virginia, United States

Site Status

University of Washington

Seattle, Washington, United States

Site Status

Charité Universitätsmedizin Berlin - Campus Benjamin Franklin

Berlin, , Germany

Site Status

Charité Universitätsmedizin Berlin - Campus Virchow Klinikum

Berlin, , Germany

Site Status

University of Heidelberg

Heidelberg, , Germany

Site Status

Ludwig-Maximilians-University

Munich, , Germany

Site Status

Klinikum rechts der Isar of the Technical University of Munich

Munich, , Germany

Site Status

University of Pecs

Pécs, , Hungary

Site Status

University of Szeged, Albert Szent Gyorgi Medical Center

Szeged, , Hungary

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Germany Hungary

References

Explore related publications, articles, or registry entries linked to this study.

Ward MD, Weber A, Merrill VD, Welch RD, Bazarian JJ, Christenson RH. Predictive Performance of Traumatic Brain Injury Biomarkers in High-Risk Elderly Patients. J Appl Lab Med. 2020 Jan 1;5(1):91-100. doi: 10.1093/jalm.2019.031393.

Reference Type BACKGROUND
PMID: 32445344 (View on PubMed)

Bazarian JJ, Biberthaler P, Welch RD, Lewis LM, Barzo P, Bogner-Flatz V, Gunnar Brolinson P, Buki A, Chen JY, Christenson RH, Hack D, Huff JS, Johar S, Jordan JD, Leidel BA, Lindner T, Ludington E, Okonkwo DO, Ornato J, Peacock WF, Schmidt K, Tyndall JA, Vossough A, Jagoda AS. Serum GFAP and UCH-L1 for prediction of absence of intracranial injuries on head CT (ALERT-TBI): a multicentre observational study. Lancet Neurol. 2018 Sep;17(9):782-789. doi: 10.1016/S1474-4422(18)30231-X. Epub 2018 Jul 24.

Reference Type RESULT
PMID: 30054151 (View on PubMed)

Bazarian JJ, Welch RD, Caudle K, Jeffrey CA, Chen JY, Chandran R, McCaw T, Datwyler SA, Zhang H, McQuiston B. Accuracy of a rapid glial fibrillary acidic protein/ubiquitin carboxyl-terminal hydrolase L1 test for the prediction of intracranial injuries on head computed tomography after mild traumatic brain injury. Acad Emerg Med. 2021 Nov;28(11):1308-1317. doi: 10.1111/acem.14366. Epub 2021 Sep 7.

Reference Type DERIVED
PMID: 34358399 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ATO-06

Identifier Type: -

Identifier Source: org_study_id